• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Venrock Healthcare Capital Partners Iii, L.P. claimed ownership of 4,025,546 shares (SEC Form 3)

    2/27/25 6:42:13 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ORKA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Venrock Healthcare Capital Partners III, L.P.

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    02/10/2025
    3. Issuer Name and Ticker or Trading Symbol
    Oruka Therapeutics, Inc. [ ORKA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 4,025,546(1) I By Funds(2)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Pre-Funded Warrants (Right to Buy) (3) (3) Common Stock 224,543(4) $0.01 I By Funds(2)
    Pre-Funded Warrants (Right to Buy) (3) (3) Common Stock 300,000(5) $0.001 I By Funds(2)
    1. Name and Address of Reporting Person*
    Venrock Healthcare Capital Partners III, L.P.

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    VHCP Co-Investment Holdings III, LLC

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    VHCP Management III, LLC

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Venrock Healthcare Capital Partners EG, L.P.

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    VHCP Management EG, LLC

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Koh Bong Y

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Shah Nimish P

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. Consists of (i) 835,515 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 83,691 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,106,340 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
    2. VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
    3. The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
    4. Consists of (i) 48,928 pre-funded warrants held by VHCP3; (ii) 4,895 pre-funded warrants held by VHCP Co-3; and (iii) 170,720 pre-funded warrants held by VHCP EG.
    5. Consists of (i) 58,860 pre-funded warrants held by VHCP3; (ii) 5,880 pre-funded warrants held by VHCP Co-3; and (iii) 235,260 pre-funded warrants held by VHCP EG.
    Venrock Healthcare Capital Partners III, L.P., By: VHCP Management III, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory 02/27/2025
    VHCP Co-Investment Holdings III, LLC, By: VHCP Management III, LLC, Its: Manager, By: /s/ Sherman G. Souther, Authorized Signatory 02/27/2025
    VHCP Management III, LLC, By: /s/ Sherman G. Souther, Authorized Signatory 02/27/2025
    Venrock Healthcare Capital Partners EG, L.P., By: VHCP Management EG, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory 02/27/2025
    VHCP Management EG, LLC, By: /s/ Sherman G. Souther, Authorized Signatory 02/27/2025
    Bong Koh, By: /s/ Sherman G. Souther, Attorney-infact 02/27/2025
    Nimish Shah, By: /s/ Sherman G. Souther, Attorney-infact 02/27/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ORKA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ORKA

    DatePrice TargetRatingAnalyst
    5/22/2025$44.00Buy
    BTIG Research
    2/4/2025$20.00Outperform
    Wolfe Research
    10/11/2024$49.00Buy
    Stifel
    10/7/2024$45.00Buy
    H.C. Wainwright
    9/17/2024$44.00Outperform
    Leerink Partners
    9/16/2024Buy
    TD Cowen
    9/13/2024$40.00Buy
    Jefferies
    More analyst ratings

    $ORKA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oruka Therapeutics Announces $180 Million Private Placement

    MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka" or the "Company") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $180 million to the Company, before placement agent fees and offering expenses. The PIPE financing was led by Viking Global Investors, and included participation from both new and existing investors, including Affinity Healthc

    9/17/25 1:02:00 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

    Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-treatment remissions Well tolerated with a favorable safety profile consistent with the IL-23p19 class EVERLAST-A Phase 2a trial enrollment ongoing with data expected 2H 2026 MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced interim data from

    9/17/25 1:00:00 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 MENLO PARK, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today reported second quarter 2025 financial results and provided a corporate update. "We are very pleased to have initiated our EVERLAST-A study, and we expect nearl

    8/11/25 4:04:00 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $1,407,368 worth of shares (122,882 units at $11.45) (SEC Form 4)

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    2/27/25 6:42:49 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Oruka Therapeutics with a new price target

    BTIG Research initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $44.00

    5/22/25 8:12:44 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Wolfe Research initiated coverage on Oruka Therapeutics with a new price target

    Wolfe Research initiated coverage of Oruka Therapeutics with a rating of Outperform and set a new price target of $20.00

    2/4/25 7:08:55 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Stifel initiated coverage on Oruka Therapeutics with a new price target

    Stifel initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $49.00

    10/11/24 7:51:24 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc was granted 333,340 shares (SEC Form 4)

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    9/19/25 5:33:05 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Chief Operating Officer Sandler Laura Lee

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    7/1/25 9:26:04 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    New insider Sandler Laura Lee claimed ownership of 213,084 shares (SEC Form 3)

    3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    7/1/25 9:21:50 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    SEC Filings

    View All

    SEC Form S-3 filed by Oruka Therapeutics Inc.

    S-3 - Oruka Therapeutics, Inc. (0000907654) (Filer)

    10/3/25 5:28:47 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form S-3 filed by Oruka Therapeutics Inc.

    S-3 - Oruka Therapeutics, Inc. (0000907654) (Filer)

    10/3/25 5:19:55 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 424B3 filed by Oruka Therapeutics Inc.

    424B3 - Oruka Therapeutics, Inc. (0000907654) (Filer)

    9/22/25 4:26:35 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Oruka Therapeutics Inc.

    SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    11/21/24 6:30:53 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oruka Therapeutics Inc.

    SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    11/14/24 7:38:47 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oruka Therapeutics Inc.

    SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    11/14/24 5:49:56 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care